Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment
Psychopharmacology Bulletin · 2026-10-29 · 56 (4) · 141-152
DOI: 10.64719/pb.21624 ↗Abstract
Objective Patients with schizophrenia who receive antipsychotics carry an elevated risk of thromboembolic disease, but hemostatic and inflammatory markers vary widely between patients given the same drug. This pilot study described D-dimer, C-reactive protein (CRP), and the neutrophil-to-lymphocyte ratio (NLR) in such patients, described the distribution of CYP2D6 rs1065852 and HTR2A rs6313 genotypes, and explored whether the biomarkers differ by genotype. Method In an observational, cross-sectional analysis, the first 22 consecutive adults with schizophrenia treated for at least 4 weeks at a psychiatric hospital in Padang, Indonesia, were studied. D-dimer and CRP were measured by sandwich enzyme-linked immunosorbent assay and the two polymorphisms by Kompetitive Allele-Specific PCR. Continuous variables are reported as median (interquartile range); groups were compared with the Mann-Whitney U test and correlations assessed by Spearman rank correlation, two-sided, at an alpha of .05. Results Genotyping succeeded for all 22 samples. For rs1065852, 15 participants (68.2%) were AG and 7 (31.8%) GG, with no AA homozygotes; for rs6313, 10 (45.5%) were TT, 11 (50.0%) CT, and 1 (4.5%) CC. No participant reached the prespecified hypercoagulability threshold of 500 ng/mL (0 of 22; exact 95% CI, 0%–15.4%); median D-dimer was 64.0 ng/mL. Median CRP was 0.78 mg/L and median NLR 1.62. No biomarker differed by genotype or sex (all P ⩾ .09). Conclusion Hemostatic and inflammatory activity was low in this small clinically stable sample, and no genotype signal emerged. A genotype-based risk score is premature; a larger prospective study with a more sensitive D-dimer assay is needed.
EUVIMED